Clinical Trial Update: Benefits of Empagliflozin in Patients With Heart Failure and Reduced Ejection Fraction Without Diabetes Mellitus [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating empagliflozin in patients with heart failure with reduced ejection fraction who do not have diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Ashraf Wasfy Beshay Aziz | Conditions: Heart Failure With Reduced Ejection Fraction | Phase 4 | Status: COMPLETED